Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Background: Fulvestrant 500 mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding the effectiveness of the drug in a real-world setting. Patients and methods: This prospective, multicenter...

Full description

Bibliographic Details
Main Authors: Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini, Anna Gambaro, Antonella Ferzi, Barbara Tagliaferri, Cristina Teragni, Luca Licata, Francesco Serra, Pietro Lapidari, Antonio Bernardo
Format: Article
Language:English
Published: SAGE Publishing 2019-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835919833864

Internet

https://doi.org/10.1177/1758835919833864

Similar Items